Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Objective: Demonstrate superior efficacy of tanezumab 10 mg, 5 mg, and 2.5 mg administered IV every 8 weeks in combination with oral diclofenac SR 75 mg BID versus placebo administered IV every 8 weeks in combination with oral diclofenac SR 75 mg BID at Week 24.
Critère d'inclusion
- OSTEOARTHRITIS OF THE KNEE OR HIP